FDA
-
-
-
-
-
-
-
RedHill's RHB-204 shows comparable efficacy to RHB-104 in lab tests
-
-
-
-
-
-
-
Cumberland Pharmaceuticals gets FDA approval for expanded Caldolor indication
-
-
-
-
-
-
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE
-
-
-
-
-
-
-
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
-
-
-
-
-
-
-
Sitryx names Adam Mostafa as chief financial officer
-
-
-
-
-
-
-
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
-
-
-
-
-
-
-
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
-
322,470 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

